Axial Spondyloarthritis
One-quarter of patients with axial SpA remain flare-free after ceasing etanercept
In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.
Bimekizumab achieves significant, rapid improvements in axial spondyloarthritis
The use of bimekizumab to inhibit both interleukin-17A and IL-17F was well-tolerated and impactful in improving axial spondyloarthritis outcomes across two phase 3 trials, according to data published in the Annals of the Rheumatic Diseases.
Celecoxib added to golimumab fails to slow spine damage vs monotherapy in axial SpA
PHILADELPHIA — Combination therapy with celecoxib plus golimumab failed to show significant superiority to golimumab alone in slowing spine damage in radiographic axial spondyloarthritis, according to data presented at ACR Convergence 2022.
Treatment retention ‘high’ after infliximab biosimilar-to-biosimilar switch
PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.
EULAR/ASAS: Axial SpA management should pursue predefined treatment goal
Axial spondyloarthritis management should be guided by a predetermined treatment target, according to new recommendations published by the Assessment of Spondyloarthritis international Society and EULAR.
‘Aggressive therapy’ key in axial spondyloarthritis despite lack of T2T recommendation
SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.
FDA approves upadacitinib for non-radiographic axial spondyloarthritis
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.
Upadacitinib significantly improves non-radiographic axial SpA signs, symptoms vs placebo
Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.
Citrate-free Taltz now available
A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.
About 35% of patients with non-radiographic axial SpA told disease is ‘in their head’
ORLANDO, Fla. — Many patients with non-radiographic axial spondyloarthritis experience symptoms for nearly a decade before receiving a diagnosis, according to a presenter at the 2022 Rheumatology Nurses Society Conference.